A new approach is evolving for the treatment of cancer, which, as today’s article explains, involves “discovering pairs of genes whose combined activity is vital to cancer cells, allowing a joint attack to kill tumors in a strategy known as ‘synthetic lethality’”. For a look at two startups focused on finding cancer’s combined weaknesses – and with drug candidates entering…
Of the biotech industry, the author of today’s article notes that it “has seen its share of losses over the past couple of months but that provides us the perfect opportunity to pick up shares of stocks that could see substantial gains in the months ahead.” With that, he proceeds to highlight three undervalued biotech stocks poised to see their…
With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of…
The small-cap biotech company featured in today’s article experienced a remarkable rally over the last few months. However, with the FDA having just approved its most advanced asset, a treatment for ADHD, the author believes that this “exhausts the company’s largest catalyst, and [they] do not see any material new catalysts any time soon.” With that, and with doubts about…
“The company highlighted in today’s article “helps its customers to find the exceedingly rare cells/antibodies needed to fight cancer, inflammation etc. Basically, to find the needle in the haystack” – and as it operates in a high-growth and rapidly expanding area of biotech, the author believes that this digital cell biology company is a solid candidate for high-growth/high-risk portfolios. For…
In the biotech realm, the author of today’s article notes that “PDUFA (Prescription Drug User Fee Act) dates – the deadline of the FDA’s review of new drugs – determine whether a treatment is fit for purpose or not and a yay or nay can act as a major catalyst to send shares either soaring or crashing.” As such, he…
One of the strongest biotechs out there, a diamond in the rough, and a high-risk, high-reward play make up the three biotech stocks identified by the author of today’s article as top picks for 2021 for investors looking for even better biotech returns than those offered by broad biotech ETFs such as the SPDR S&P Biotech ETF. For a look…
Noting how difficult it can be for investors to understand what’s happening in the biotech industry generally and at specific biotech companies, the author of today’s article explains that he tends to invest “in companies that have a track record of working with existing products while successfully developing pipelines of new products” and in “picks-and-shovels companies that get paid to…
With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks…
“The premise here is simple: biotech investing is just as it was before COVID-19 and as it will be when the pandemic is finally over,” begins the author of today’s article. If one accepts this premise, what does that mean for investing in the three fronts of the war on the coronavirus (testing, treatment and vaccination)? For the author’s overview…